BIO-TECHNE Corp（TECH）の決算・業績分析
BIO-TECHNE Corpの2025年有価証券報告書をAI分析。売上高$1.2B(+5.2%)。営業利益$102M。Health Care。
目次
BIO-TECHNE Corpの2025年度 業績サマリー
BIO-TECHNE Corp（証券コード: TECH）の2025年度決算・業績分析。売上高は$1.2B（前年比+5.2%）。営業利益は$102M（前年比-50.5%）。純利益は$73M（前年比-56.3%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
BIO-TECHNE Corpの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue surged 18.7% YoY to $1.1B (XBRL), driven by strong demand for life science reagents and diagnostics.
- Net income skyrocketed 93.8% YoY to $272M (XBRL), reflecting improved operating efficiency and cost management.
- Free cash flow reached $280M (XBRL), with $161M allocated to share repurchases and $50M in dividends.
- Gross margin remained robust at 68.4% (XBRL), supported by high-value product offerings and R&D investment ($87M).
BIO-TECHNE Corpの売上高変化の要因
- •Revenue grew 18.7% YoY to $1.1B (XBRL), with a 5-year CAGR of 12.1% (XBRL). The company's diversified product portfolio and strong market position in life science reagents and diagnostics drove growth. While segment-specific revenue data is not disclosed (N/A), the Protein Sciences and Diagnostics segments are highlighted as core drivers of value (10-K).
BIO-TECHNE Corpの営業利益変化の要因
- •Profitability metrics improved significantly: operating income rose 25.0% YoY to $297M (XBRL), and net income surged 93.8% YoY to $272M (XBRL). Margins remained strong, with gross margin at 68.4% (XBRL), operating margin at 26.8% (XBRL), and net margin at 24.6% (XBRL).
BIO-TECHNE Corpの事業リスクと対応
Global economic downturns could reduce demand, disrupt supply chains, and increase uncollectible receivables (10-K).
Geopolitical conflicts (e.g., Ukraine, Israel-Gaza) and U.S.-China trade tensions may harm operations and revenue (10-K).
Expansion into emerging markets exposes the company to currency risks, regulatory hurdles, and corruption (10-K).
U.S. healthcare policy changes, like government price negotiations, could reduce sales revenue (10-K).
Political/military conflicts may cause broader economic disruptions, affecting global operations (10-K).
BIO-TECHNE Corpの事業内容
BIO-TECHNE Corp (TECH) operates in the life science industry, developing, manufacturing, and selling reagents, instruments, and services for research, diagnostics, and bioprocessing (10-K). Its two operating segments are Protein Sciences (biological reagents, proteomic tools) and Diagnostics and Genomics (diagnostic assays, exosome-based diagnostics). The company leverages R&D investment ($87M), strategic acquisitions (e.g., Lunaphore), and a global brand to maintain a competitive edge (10-K).
BIO-TECHNE CorpのAI業績分析レポート（2024年度）
BIO-TECHNE Corp (TECH) Annual Report Analysis FY2024
Highlights
Business Overview
BIO-TECHNE Corp (TECH) operates in the life science industry, developing, manufacturing, and selling reagents, instruments, and services for research, diagnostics, and bioprocessing (10-K). Its two operating segments are Protein Sciences (biological reagents, proteomic tools) and Diagnostics and Genomics (diagnostic assays, exosome-based diagnostics). The company leverages R&D investment ($87M), strategic acquisitions (e.g., Lunaphore), and a global brand to maintain a competitive edge (10-K).
Revenue Analysis
Revenue grew 18.7% YoY to $1.1B (XBRL), with a 5-year CAGR of 12.1% (XBRL). The company's diversified product portfolio and strong market position in life science reagents and diagnostics drove growth. While segment-specific revenue data is not disclosed (N/A), the Protein Sciences and Diagnostics segments are highlighted as core drivers of value (10-K).
Profitability Analysis
Profitability metrics improved significantly: operating income rose 25.0% YoY to $297M (XBRL), and net income surged 93.8% YoY to $272M (XBRL). Margins remained strong, with gross margin at 68.4% (XBRL), operating margin at 26.8% (XBRL), and net margin at 24.6% (XBRL).
Balance Sheet Analysis
The balance sheet reflects a healthy capital structure: equity ratio of 74.5% (XBRL), current ratio of 4.84x (XBRL), and $181M in cash (XBRL). Total assets grew from $1.9B in FY2020 to $2.6B in FY2024 (XBRL), while total equity increased from $950M to $2.0B (XBRL).
Cash Flow Analysis
Operating cash flow was $325M (XBRL), with $45M spent on CapEx (XBRL). Free cash flow totaled $280M (XBRL), with $161M used for share repurchases and $50M paid in dividends (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 225 days (XBRL), with receivables days at 72, inventory days at 180, and payables days at 27 (XBRL).
Risks
Outlook
N/A (no management guidance or forward-looking trends explicitly mentioned in the 10-K or XBRL data).
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 643M | 714M | 739M | 931M | 1.1B | 1.1B |
| Operating Income | 136M | 147M | 157M | 237M | 297M | 299M |
| Net Income | 126M | 96M | 229M | 140M | 272M | 285M |
| Total Assets | 1.9B | 2.0B | 2.3B | 2.3B | 2.6B | 2.7B |
| Total Equity | 950M | 1.4B | 1.6B | 1.7B | 2.0B | 1.7B |
| Operating Cash Flow | 170M | 182M | 205M | 352M | 325M | 254M |
Health Careの企業一覧
BIO-TECHNE Corpと同じ「Health Care」セクターの企業